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ABSTRACT 
This study evaluated the possible protective effect of Crocus sativus L. (saffron) in the treatment of renal calculi. 
Aqueous extract of saffron (25, 50 and 100 mg/kg, daily) was administered intraperitoneally in two regimens of 
protective or curative, using male Wistar rats. Urolithiasis was induced by ethylene glycol (% 0.75) in drinking 
water. Urine was collected for biochemical analysis and the kidneys were prepared for total lipid peroxide and 
histological evaluation. Ethylene glycol feeding resulted in an increased urine output, renal excretion of oxalate 
and decreased excretion of citrate and magnesium. Saffron did not show diuretic effect; however, it significantly 
reduced the elevated urinary oxalate in prophylactic (50 and 100 mg/kg) and curative (100 mg/kg) studies. Only 
the high dose of prophylactic regimen restored citrate concentration of urine. Increased number of calcium oxa-
late crystals deposits in the kidney tissue of calculogenic rats was significantly reverted by the prophylactic and 
high dose of curative saffron treatment. Malondialdehyde (MDA, a lipid peroxidation product) in the kidneys 
was increased following the lithogenic treatment; however, prophylactic (50, 100 mg/kg) and curative (100 
mg/kg) regimens with saffron reduced the elevated levels of MDA. Results in the current study indicate that saf-
fron can protect against ethylene glycol induced calcium oxalate (CaOx) nephrolithiasis. The mechanisms under-
lying this effect are mediated possibly through effect on the urinary concentration of stone-forming constituents 
and an antioxidant effect. 
 
Keywords: Crocus sativus, saffron, kidney stone, renal calculus, nephrolithiasis, hyperoxaluria, calcium oxalate, 
ethylene glycol, oxidative stress 
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INTRODUCTION 
Kidney stone disease has become a rising 
problem and the third prevalent disorder af-
fecting the urinary tract with high recur-
rence. This disorder involves a complex of 
events, such as crystal nucleation, supersatu-
ration, growth, aggregation, retention within 
renal tubules and migration to the renal pa-
pillary surfaces (Moe, 2006). The majority 
(up to 80 %) of all stones are mainly com-
posed of CaOx. Drawbacks of current treat-
ments necessitate finding new drugs and 
many remedies, taken from plants have been 
reported to be effective treatments for uro-
lithiasis with little adverse effects (Butter-
weck and Khan, 2009). 
Saffron, the dried stigma from the flower 
of C. sativus L., has been used as a famous 
dietary ingredient and coloring agent since 
ancient times (Abdullaev, 1993). In folklore 
medicine, it has also recommended for nu-
merous ailments including cough, asthma, 
menstruation problems, insomnia, pain, col-
ic, chronic uterine hemorrhage, painful uri-
nation and kidney stone (Hosseinzadeh and 
Nassiri-Asl, 2013). Avicenna, a Persian phy-
sician and the most famous philosopher–
scientists of Islamic word, described details 
of a remedy, consisted of saffron plus honey 
prescribed to produce diuresis and facilitate 
passage of kidney stone (Mousavi and 
Bathaie, 2011). The traditional uses of saf-
fron are now supported by different studies. 
Saffron and its bioactive ingredients have 
been reported to possess anti-cancer (Abe 
and Saito, 2000), anti-oxidant (Hosseinzadeh 
et al., 2009), plasma lipid lowering effect 
and insulin resistance improvement (Sheng 
et al., 2008), anti-convulsant (Hosseinzadeh 
et al., 2008), anti-depressant (Hosseinzadeh 
et al., 2003), memory improvement (Hosse-
inzadeh and Ziaei, 2006), antinociceptive 
and anti-inflammatory properties (Hosse-
inzadeh and Younesi, 2002; Hosseinzadeh 
and Shariaty, 2007). 
The present study evaluated for the pos-
sible therapeutic potential of aqueous extract 
of C. sativus in experimentally induced cal-
cium oxalate urolithic in two regimens of 
prophylactic and curative in rats. 
 
MATERIAL AND METHODS 
Animals 
Male Wistar rats weighing 250–300 g 
were obtained from the animal house of the 
School of Pharmacy, Mashhad University of 
Medical Sciences, Iran. Animals were kept 
in a 12 h light–dark cycle environment and 
were fed normal laboratory chow food ad 
libitum. All procedures were approved by 
Mashhad University of Medical Sciences 
and followed the Internationally Accepted 
Principles for Laboratory Animal Use and 
Care.  
 
Materials 
The stigmas of C. sativus L. was pur-
chased from Novin Saffron Co. (Mashhad, 
Iran) and analyzed in accordance to ISO/TS 
259–2. Hydrochlorothiazide (HCTZ) was a 
gift from Darupaksh Pharmaceutical Co., 
Tehran, Iran. Potassium citrate was pur-
chased from Sepidaj Pharmaceutical Co., 
Tehran, Iran. Malondialdehyde was obtained 
from Fluca (Switzerland). Ethylene glycol 
(EG) and ammonium chloride (AC) were 
provided from Merck (Germany). All com-
pounds were dissolved in normal saline 
(0.9 %) immediately before injection.  
 
Preparation of extract 
Aqueous extract was prepared by mixing 
saffron powder with distilled water at a ratio 
of 1:50 respectively, shacked in an incubator 
for 48 h, centrifuged at a rate of 4000 g for 
10 min and the supernatant was separated. In 
this stage, sediment was suspended in the 
half amount of mentioned distilled water and 
process was repeated again. The later solu-
tion was added to first one and stored in a 
−20 °C freezer. The total solution was 
freeze-dried for sublimating of solvent. 
 
Stone induction 
Ethylene glycol plus ammonium chloride 
model was used to induce urolithiasis (Khan, 
1997). 
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Experimental design 
Sixty-six animals were randomly divided 
into eleven groups (I-XI) containing six rats 
each. Animals in group I received tap drink-
ing water for 30 days (intact control). Ani-
mals in group II were treated with the high 
dose of aqueous extract for 30 days (saffron 
control). All remaining groups received cal-
culi inducing treatment for 30 days, com-
prised of 0.75 % v/v ethylene glycol and 1 % 
w/v ammonium chloride in drinking water 
ad libitum for 3 days. Following this, treat-
ment was switched to only 0.75 % EG for 27 
days. Stone forming control group (G III), as 
a negative control, received only EG plus 
AC. As a positive control, groups IV and V 
received potassium citrate (2.5 g/kg) and hy-
drochlorothiazide (10 mg/kg), respectively 
from 1st day to 30th day of calculi induction. 
Groups VI-VIII served as prophylactic 
treatment groups and received extract at dos-
es of 25, 50 and 100 mg/kg respectively 
from 1st day to 30th day of calculi induction. 
Groups IX-XI were given aq. extract of saf-
fron 25, 50 and 100 mg/kg respectively from 
14th day to 30th day of calculi induction and 
served as curative treatment group. Extract 
and standard drugs were dissolved in dis-
tilled water and given once daily by intraper-
itoneal route. Dosage selection was based on 
previous studies (Hosseinzadeh and Younesi, 
2002; Hosseinzadeh and Shariaty, 2007). 
 
Collection and analysis of urine for  
biochemical assays 
All animals were kept in individual met-
abolic cages and 24 h urine samples were 
collected on 0, 1, 7, 14 and 30th day of calcu-
li induction treatment. The volume of urine, 
oxalate, citrate, phosphate, magnesium and 
protein excreted out, were measured at the 
respective time points. 
Determination of diuretic activity was 
performed during the first 24 hours after ad-
ministration of compounds and HCTZ (10 
mg/kg) was used as a standard diuretic drug 
(Lipschitz et al., 1943). 
Following volume determination of 
urine, samples were stored at -20 °C until 
analyzed. 
 
Collection and analysis of tissue for  
histological assays 
After the last urine collection, animals 
were anaesthetized and killed. The kidneys 
were immediately excised and washed in ice-
cold saline. The right kidneys were fixed in 
10 % neutral buffered formalin. The 5 μm 
thick sections were stained via a haematoxy-
lin–eosin solution and examined by light mi-
croscopy. The instances of stone depositions 
were counted in ten microscopic fields and 
given a score as follows: Number of tubules 
filled by stone/total number of tubules in the 
field 100. 
 
Collection and analysis of tissue for  
measurement of lipid peroxidation 
The left kidneys (200 mg) were worked 
into 10 % homogenate in 1.15 % potassium 
chloride solution (2 ml), to estimate lipid  
peroxidation by measuring the MDA content 
by thiobarbituric acid reactive method 
(Uchiyama and Mihara, 1978). 3 ml phos-
phoric acid (1 %) and 1 ml TBA (0.6 %) 
were added to 0.5 ml of homogenate in a 
centrifuge tube. After mixing, all samples 
and standards (a set of MDA standards over 
the concentration range of 0-50 nmol/ml) 
were heated at 100 °C for 45 min and cooled 
by using water. 4 ml n-butanol was added to 
the mixture and vortex-mixed for 1 min fol-
lowed by centrifugation at 3000 rpm for 15 
minutes. The organic layer was transferred to 
a fresh tube and its absorbance was read at 
525 nm. Levels of MDA were expressed as 
nmol/mg of tissue. 
 
Statistical analysis 
The results were expressed as mean ± 
standard error mean (SEM). The statistical 
significance was assessed using two-way 
analysis of variance (ANOVA) followed by 
Bonferroni’s comparison test or by Student's 
t-test.The crystal deposit number and bio-
chemical data were analyzed by one-way 
EXCLI Journal 2015;14:411-422 – ISSN 1611-2156 
Received: July 26, 2014, accepted: March 09, 2015, published: March 12, 2015 
 
 
414 
ANOVA followed by Tukey’s for pair wise 
comparison. The value of P < 0.05 was con-
sidered significant.  
 
RESULTS 
Effect on the urine output 
Before the start of treatment (day 0), bio-
chemical parameters were not significantly 
different among all the groups. On day 1 af-
ter the stone induction, the reference diuretic 
drug, hydrochlorothiazide (10 mg/kg) in-
duced diuresis as compared to intact control 
animals (P<0.05). Co-treatment with aque-
ous extract did not change urine output at 
this time indicating saffron could not have 
diuretic effect.  
Urinary volume was gradually increased 
after the stone induction treatment; however 
it was significantly higher than in the intact 
control group 30 days after administration (P 
< 0.05). Different dosages of aq. extract of 
saffron reduced urine volume of animals at 
this time although not to a significant extent 
(Table 1).  
 
Effect on the urinary parameters 
As indicated in Table 2, 24-hour oxalate 
excretion was increased in negative control 
group and it was significantly higher than 
that in the intact control group 14 (P< 0.001) 
and 21 (P< 0.001) days after EG+AC treat-
ment. Simultaneous treatment with 100 mg/ 
kg of aqueous extract reduced the increase in 
urinary oxalate excretion on days 14 and 30 
(P < 0.05, P < 0.001 respectively). Similar 
results were obtained when rats were treated 
with k-citrate as a positive control. Lower 
dose (50 mg/kg) in prophylactic regimen of 
saffron’s extract reversed the increased lev-
els of oxalate only on day 30 (P < 0.01). In 
curative regimen only the high dose of 100 
mg/kg significantly (P < 0.01) reduced the 
elevation of renal oxalate content, on day 30 
(Table 2).  
Increased excretion of phosphate in uro-
lithic group was not statistically significant 
and remained comparable to that of intact 
control animals. Treated groups also did not 
show any statistically significant change in 
this parameter. 
Urinary protein loss (proteinuria) was 
observed after 14 days of stone induction (P 
< 0.001) and remained significantly different 
until the 30th day (P < 0.001), as compared to 
intact control group (Table 2). The co-
administration of aqueous extract of saffron 
at the dose of 100 mg/kg in prophylactic 
study prevented the loss in protein on days 
14 and 30 (P < 0.05) vs. lithogenic group.  
Urinary citrate excretion was gradually 
decreased by stone inducing treatment, as it 
was significantly lower than that of the intact 
control group 14 and 21 days after admin-
istration (P<0.05). However, supplementa-
tion with prophylactic regimen of 100 mg/kg 
of extract significantly prevented the decline 
in the levels of citrate on day 30 (P<0.05, 
Table 3). Potassium citrate, a well-known 
antilithiatic drug also normalized urinary cit-
rate levels as compared to lithiatic control 
group (P<0.01). 
Magnesium level of urine was not altered 
to a significant level in the lithiatic group 
and remained comparable to that of intact 
control animals (Table 3). 
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Table 1: Effect of aqueous extract of C. sativus on volume (ml) of rats in the urolithiasis induced rats 
Group 
(n=6) I II III IV V VI VII VIII IX X XI 
Volume (ml) 
Day 0 6.1 ± 0.1 6.2 ± 0.9 7.05 ± 0.36 6.5 ± 1.24 6.1 ± 0.3 7.1 ± 0.7 6. 3± 0.51 6.8 ± 0.34 5.33 ± 0.43 6.16 ± 0.3 5.8 ± 0.4 
Day 1 6.8 ± 0.2 6.1 ± 0.6 6.91 ± 0.53 6.83 ± 0.73 10.2 ± 0.8** 7 ± 0.5 6.4 ± 0.7 8.3 ± 0.5 6.83 ± 0.17 7.1 ± 0.27 7.1 ± 0.6 
Day 7 6.8 ± 0.15 7.2 ± 1.1 7.5 ± 0.57 6.5 ± 0.92 6.3 ± 0.34 8.3 ± 0.72 6.5 ± 0.9 6.8 ± 0.66 7.25 ± 0.66 7.25 ±  0.78 6.3 ± 0.68 
Day 14 7.4 ± 0.1 6.08 ± 0.8 8.16 ± 0.76 7.75 ± 1.08 8 ± 0.3 9.1 ± 0.5 7.83 ± 0.74 7.8 ± 1.03 8.16 ± 0.48 8.2 ± 0.61 7.1 ± 0.9 
Day 30 7.1 ± 0.2 6.3 ± 0. 8 9.2 ± 0.98 8.75 ± 0.58 8.2 ± 0.4 10 ± 0.3 8.7 ± 0.72 8.8 ± 0.55 9 ± 0.87 9.9 ± 0.72 7.7 ± 0.97 
I: Intact control; II: Saffron control; III: Negative control; IV, V: Positive controls (k-citrate, HCTZ), VI-VIII: Prophylactic treated aqueous extract of C. sativus (25, 50 and 100 mg/kg, i.p); IX-XI: Cu-
rative treated aqueous extract of C. sativus (25, 50 and 100 mg/kg, i.p). Values are expressed as mean ± SEM. *P< 0.05 vs. lithiatic group (G III) by two way ANOVA with repeated measure fol-
lowed by Bonferroni’s post hoc test. P< 0.05 represents difference between day 0 and days 1, 7, 14 or 30 of the lithiatic group (III) by paired t test.  
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Table 2: Effect of aqueous extract of C. sativus on urinary oxalate, phosphate and total protein levels in urolithiasis induced rats 
Group 
(n=6) I III IV V VI VII VIII IX X XI 
Oxalate (mg/24 h) 
Day 0 2.64 ± 0.18 2.85 ± 0.15 2.7 ± 0.48 2.8 ± 0.16 3.08 ± 0.26 2.65 ± 0.18 2.9 ± 0.15 2.43 ± 0.21 2.39 ± 0.12 2.43 ± 0.19 
Day 1 2.72 ± 0.3 3.29 ± 0.27 2.99 ± 0.34 3 ± 0.4 3.45 ± 0.55 3.13 ± 0.38 3.53 ± 0.22 3.68 ± 0.62 2.75 ± 0.12 2.91 ± 0.23 
Day 7 2.7 ± 0.22 4.7 ± 0.44 2.68 ± 0.36 3.9 ± 0.15 3.93 ± 0.51 3.36 ± 0.27 2.89 ± 0.28 3.49 ± 0.11 2.83 ± 0.33 2.62 ± 0.26 
Day 14 2.85 ± 0.13*** 5.6 ± 0.76 3.11 ± 0.45* 3.36 ± 0.19** 3.88 ± 0.22 3.77 ± 0.61 3.32 ± 0.44* 4.92 ± 0.64 5.09 ± 0.5 3.92 ± 0.41 
Day 30 3.08 ± 0.4*** 7.8 ± 0.64 3.81 ± 0.21*** 4.3 ± 0.4*** 5.33 ± 0.52 4.68 ± 0.93** 4.54 ± 0.73*** 5.72 ± 0.69 5.74 ± 0.88 4.82 ± .58** 
Phosphate (mg/24 h) 
Day 0 5.42 ± 0.54 5.54 ± 0.38 5.3 ± 1.45 5.15 ± 0.21 5.63 ± 0.92 5.03 ± 0.66 5.16 ± 0.54 4.94 ± 0.33 5.5 ± 0.41 4.94 ± 0.36 
Day 1 5.11 ± 0.45 5.6 ± 0.55 5.71 ± 0.58 5.8 ± 0.56 5.59 ± 0.63 4.98 ± 0.93 5.48 ± 0.48 5.22 ± 0.43 5.95 ± 0.24 6.04 ± 0.69 
Day 7 5.05 ± 0.44 6.55 ± 0.53 5.98 ± 0.76 4.9 ± 0.26 6.11 ± 0.9 5.17 ± 1.02 4.94 ± 0.65 5.17 ± 1.12 5.9 ± 0.85 5.39 ± 0.53 
Day 14 5.51 ± 0.3 6.4 ± 0.82 6.22 ± 1.33 5.2 ± 0.23 6.38 ± 0.54 5.27 ± 1.44 5.53 ± 0.99 5.84 ± 0.59 6.54 ± 0.26 6.11 ± 0.69 
Day 30 5.65 ± 0.5 7.26 ± 0.93 6.3 ± 1.46 4.9 ± 1.07 6.59 ± 0.74 6.01 ± 0.6 5.45 ± 0.43 5.94 ± 0.8 7.03 ± 0.61 6.46 ± 0.64 
Protein (mg/24 h) 
Day 0 0.62 ± 0.045 0.9 ± 0.1 0.65 ± 0.12 0.7 ± 0.04 0.61 ± 0.07 0.58 ± 0.04 0.72 ± 0.04 0.73 ± 0.11 0.67 ± 0.08 0.73 ± 0.11 
Day 1 0.72 ± 0.07  0.85 ± 0.12 0.76 ± 0.09 0.9 ± 0.1 0.64 ± 0.05 0.68 ± 0.09 0.9 ± 0.05 0.84 ± 0.12 0.7 ± 0.02 0.72 ± 0.04 
Day 7 0.86 ± 0.05 1.21 ± 0.15 0.8 ± 0.14 0.7 ± 0.05 0.87 ± 0.13 0.82 ± 0.15 0.73 ± 0.05 1.39 ± 0.46 0.77 ± 0.12 0.82 ± 0.09 
Day 14 0.88 ± 0.12*** 2.5 ± 0.2 1.28 ± 0.21* 1.24 ± 0.18* 2.6 ± 0.56 1.3 ± 0. 1 1.2 ± 0.25* 1.76 ± 0.19 1.18 ± 0.19** 1.5 ± 0.29 
Day 30 0.84 ± 0.08*** 2.9 ± 0.23 1.47 ± 0.2* 1.5 ± 0.12 2.9 ± 0.48 2.03 ± 0.27 1.6 ± 0.25* 2.82 ± 0.55 2.13 ± 0.4 1.7 ± 0.27 
I: Intact control; III: Negative control; IV, V: Positive controls (k-citrate, HCTZ), VI-VIII: Prophylactic treated aqueous extract of C. sativus (25, 50 and 100 mg/kg, i.p); IX-XI: Curative treated aqueous extract of C. sativus 
(25, 50 and 100 mg/kg, i.p). Values are expressed as mean ± SEM. Values in a column with different superscript letters are significantly different *P< 0.05, **P< 0.01, ***P< 0.001 vs. lithiatic group (G III) by two way 
ANOVA with repeated measure followed by Bonferroni’s post hoc test. P< 0.05 and P< 0.01 comparisons are made between day 0 and days 1, 7, 14 or 30 of the lithiatic group (III) with paired t test.  
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Table 3: Effect of aqueous extract of C. sativus on urinary citrate and magnesium levels in urolithiasis induced rats 
Group (n=6) I III IV V VI VII VIII IX X XI 
Citrate (mg/24 h) 
Day 0 4.06 ± 0.49 3.6 ± 0.16 3.83 ± 0.44 3.9 ± 0.36 3.8 ± 0.4 3.64 ± 0.25 3.48 ± 0.1 3.38 ± 0.52 4.07 ± 0.38 3.65 ± 0.3 
Day 1 3.81 ± 0.48 3.76 ± 0.23 4 ± 0.44 3.64 ± 0.42 3.5 ± 0.42 3.46 ± 0.49 3.8 ± 0.2 3.48 ± 0.51 3.5 ± 0.41 3.27 ± 0.27 
Day 7 4 ± 0.41 3.2 ± 0.23 3.62 ± 0.45 3.5 ± 0.18 3 ± 0.22 2.87 ± 0.39 3.4 ± 0.3 2.97 ± 0.37 2.96 ± 0.42 2.91 ± 0.3 
Day 14 4.2 ± 0.24* 2.8 ± 0.23 3.9 ± 0.23 3.2 ± 0.3 2.65 ± 0.54 3.24 ± 0.15 3.88 ± 0.28 2.67 ± 0.39 3.1 ± 0.24 3.06 ± 0.41 
Day 30 4.2 ± 0.26* 2.4 ± 0.3 4.55 ± 0.17* 3.5 ± 0.46 2.94 ± 0.22 3.19 ± 0.23 3.9 ± 0.4* 2.54 ± 0.31 3.17 ± 0.41 2.98 ± 0.32 
Magnesium (mg/24h) 
Day 0 2.36 ± 0.26 2.85 ± 0.19 2.47 ± 0.16 2.29 ± 0.16 2.45 ± 0.33 2.38 ± 0.27 2.57 ± 0.23 2.1 ± 0.11 2.29 ± 0.15 2.15 ± 0.14 
Day 1 2.57 ± 0.25 2.62 ± 0.36 2.46 ± 0.42 2.38 ± 0.45 2.44 ± 0.11 2.36 ± 0.3 2.69 ± 0.18 2.41 ± 0.15 2.41 ± 0.16 2.33 ± 0.22 
Day 7 2.61 ± 0.3 2.55 ± 0.31 2.31 ± 0.16 2.15 ± 0.21 2.23 ± 0.28 2.35 ± 0.24 2.54 ± 0.29 2.46 ± 0.28 2.49 ± 0.19 2.33 ± 0.25 
Day 14 2.79 ± 0.34 2 ± 0.31 1.86 ± 0.21 2.3 ± 0.25 2.23 ± 0.16 2.13 ± 0.41 2.56 ± 0.35 2.13 ± 0.33 2.32 ± 0.14 2.45 ± 0.22 
Day 30 2.62 ± 0.11 1.84 ± 0.34 1.74 ± 0.26 2.48 ± 0.47 1.78 ± 0.2 1.79 ± 0.26 2.38 ± 0.35 2.33 ± 0.6 2.28 ± 0.25 2.63 ± 0.47 
I: Intact control; III: Negative control; IV, V: Positive controls (k-citrate, HCTZ), VI-VIII: Prophylactic treated aqueous extract of Crocus sativus (25, 50 and 100 mg/kg,  i.p); IX-XI: Curative treated aqueous extract of C. 
sativus (25, 50 and 100 mg/kg,  i.p). Values are expressed as mean ± SEM. *P< 0.05 vs. lithiatic control group (G III) by two way ANOVA with repeated measure followed by Bonferroni’s post hoc test. P< 0.05 repre-
sents comparisons made between day 0 and days 1, 7, 14 or 30 of lithiatic group (III) with paired t test.  
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Histopathologic findings 
Examination of kidney paraffin sections 
showed that in the lithogenic treatment-
induced group deposition of the calcium oxa-
late crystals in the renal tissue was increased 
with some interstitial infiltration whereas no 
crystal deposition was observed in intact 
control animals (Figure 1 and Table 4). 
However, prophylactic therapy with 
aqueous extract of saffron (50, 100 mg/kg) 
significantly (P < 0.01) and curative therapy 
partially dissolved the calcium oxalate stones 
in renal tissue (P < 0.05). 
 
 
 
Figure 1: Represented light microscopy of paraffin sections viewed under polarized light of rat kidneys 
in each groups. Arrows indicate the crystals in the cortex, tubular, and medulla (x40) of rat at 30 days. 
There were no deposits in intact control group (A). Ethylene-glycol-induced urolithic group showed 
significant increased levels of crystal deposits (B). Positive control group (k citrate, C); Preventive 
treated groups of Crocus sativus aqueous extract (25, 50 and 100 mg/kg, D, E, F respectively) and 
curative treated groups (50 and 100 mg/kg, G, H respectively). 
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Table 4: Effect of aqueous extract of Crocus sativus on the CaOx crystal deposition number in uro-
lithiasis induced rats 
Group (n=6) I III IV V VI VII VIII IX X XI 
Tubules including 
CaOx crystal  
deposition/Total 
of tubules in the 
field40 
0*** 
15.2 
±  
2.2 
0***
2.5 
± 
1.7* 
5.9 
± 
2.4 
2 
± 
1.3**
0.5 
± 
0.5** 
11.5 
± 
3.5 
8.3 
± 
3.5 
5.2 
± 
2.4* 
I: Intact control; III: Negative control; IV, V: Positive controls (k-citrate, HCTZ), VI-VIII: Prophylactic treated aqueous extract of 
Crocus sativus (25, 50 and 100 mg/kg, i.p); IX-XI: Curative treated aqueous extract of C. sativus (25, 50 and 100 mg/kg, i.p). 
Values are expressed as mean ± SEM. *P< 0.05, **P< 0.01, *** P< 0.001 vs. lithiatic control group (G III) by one way ANOVA 
followed by Tukey’s post hoc test.  
 
 
 
Effect on the lipid peroxidation 
Renal stone induction caused significant 
increase (P<0.01) in the lipid peroxidation of 
kidney tissue of the Group II as indicated 
with higher MDA levels (Figure 2). Animals 
receiving a simultaneous treatment with 
prophylactic (100 and 50 mg/kg, P<0.01, 
P<0.05, respectively) and curative regimens 
(100 mg/kg, P < 0.05) of extract had lower 
MDA levels as compared to lithiatic control. 
DISCUSSION 
The annual incidence and prevalence of 
nephrolithiasis is reported to be increasing 
worldwide, along with a decrease in the age 
of onset, perhaps due to the result of change 
in lifestyle, diet and climate (Zuckerman and 
Assimos, 2009). Some natural therapeutic 
agents have been shown protective effects in 
different in vitro and in vivo models of uro-
lithiasis possibly due to multiple constituents, 
 
Figure 2: Concentration of MDA in the kidney tissue of different treated groups. Data was shown as 
mean ± S.E.M. Significance was determined by One-Way ANOVA followed by Tukey Post-hoc test: 
*P<0.05, ** P< 0.01 versus EG-treated group (n = 4). 
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acting through different pathways (Gandhi et 
al., 2013; Hosseinzadeh et al., 2010). As uri-
nary system of male rats resembles that of 
humans, this genus was selected to induce 
urolithiasis (Khan, 1997). Evidence in previ-
ous studies indicated that 14 days admin-
istration of EG, which increases urinary con-
centration of oxalate results into the for-
mation of renal calculi composed mainly of 
calcium oxalate (Fan et al., 1999; Khan, 
1997). The biochemical mechanism for this 
process is related to nonspecific dehydro-
genase of EG, metabolized to oxalic acid and 
leads to hyperoxaluria, a major risk factor in 
the pathogenesis of kidney stones. It seems 
that hyperoxaluria provides an environment 
appropriate to stone formation by forming 
calcium oxalate deposition. 
Ammonium chloride accelerating stone 
formation through metabolic acidosis, was 
added to the regimen of EG for 3 days (Fan 
et al., 1999). 
Oxalate excretion was progressively in-
creased in EG/AC-treated groups. Whereas, 
on the administration of aqueous extract of 
saffron, oxalate excretion decreased in a dose 
dependent manner. 
When tested for diuretic activity, HCTZ 
induced diuresis in rats over a period of 24 h. 
However, saffron did not increase urine out-
put at this time. As in folklore medicine saf-
fron has been said to possess diuretic activi-
ty, this effect might appear in higher or low-
er doses that were not evaluated in our study 
or after 30 days of the extract administration. 
Urine level of citrate was lower in rats 
treated with EG/AC than intact control ani-
mals. Low level of citrate is an important 
risk factor for the stone formation in kidney 
(Zuckerman and Assimos, 2009). Citrate 
complexes with calcium can increase its sol-
ubility and reduce free calcium content in the 
urine. Urinary citrate was improved by 
prophylactic treatment of high dose aqueous 
extract (100 mg/kg) similar to potassium cit-
rate. 
Urine elements such as phosphate and 
magnesium were not significantly affected 
by either urolithiasis or saffron extract treat-
ments which is in agreement with some pre-
vious studies (Shirfule et al., 2013). 
The excretion of protein was increased in 
EG/AC treated animals and prevented by 30 
days administration of aqueous extract of 
saffron (100 mg/kg).  
Microscopic examination of kidney sec-
tions derived from EG/AC induced urolithic 
rats showed crystal deposition in the kidneys 
of lithogenic group along with interstitial 
inflammation that might be attributed to oxa-
late. The concurrent administration of extract 
in prophylactic regimen (50, 100 mg kg) 
prevented calcium oxalate crystal deposition 
in the kidney. The extract at a dose of 
100 mg/kg in the curative study also partially 
reduced the number of crystal deposition. 
It has been indicated that high levels of 
oxalate and CaOx crystals lead to cellular 
injury, increased levels of reactive oxygen 
species and lipid peroxidation (Thamilselvan 
et al., 2003). Lipid peroxidation has been 
suggested to be a predisposing factor for 
subsequent CaOx crystal deposition (Selvam 
and Bijikurien, 1991). The exact mecha-
nism(s) by which the saffron exerts its pro-
tective effects against EG-induced nephro-
lithiasis is not yet understood. In this study 
antioxidant potential of aqueous extract in 
the kidney of rats was evaluated by lipid per-
oxidation inhibitory activity. A significant 
increase in the MDA contents, representing 
lipid peroxidation, was observed in the kid-
neys of rats treated with ethylene glycol 
compared to that of intact control. Animals 
receiving aqueous extract of saffron exhibit-
ed lower MDA levels as compared to lithiat-
ic control group.  
Although supplementation with the 
50 mg/kg of extract in prophylactic regimen 
and 100 mg/kg of curative regimen attenuat-
ed urinary oxalate levels and oxidative 
stress, none of them decreased proteinuria, 
probably due to the partial existence of kid-
ney stones. Saffron active ingredients includ-
ing crocetin, picocrocin (a glycosidic precur-
sor of safranal), safranal, crocin (glycosides 
of the carotenoid crocetin) and other terpe-
noids, alkaloids and saponin contents may 
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prevent the lipid peroxidation-induced renal 
damage caused by calcium oxalate crystal 
deposition in the kidney (Abe and Saito, 
2000; Alavizadeh and Hosseinzadeh, 2014; 
Moraga et al., 2009; Rezaee and Hosseinza-
deh, 2013). Antioxidant and anti-inflam-
matory activities of saffron and its bioactive 
components have been demonstrated in vari-
ous studies. For example cerebral ischemia-
induced oxidative damage was attenuated by 
safranal in the hippocampus of rats (Hossein-
zadeh and Sadeghnia, 2005). Cisplatin-
induced nephrotoxicity prevented by 50 mg/ 
kg of the ethanolic extract of saffron and 
crocin through diminution of oxidative 
stress. Crocin prevented cytotoxicity induced 
by a potent neurotoxin, acrylamide, via de-
creasing apoptosis as well as ROS generation 
inhibition (Mehri et al., 2012). In a study by 
Yoshino et al. (2011), crocetin reduced reac-
tive oxygen species in the brain of stroke-
prone spontaneously hypertensive rats. 
Crocin and crocetin reduced LPS-induced 
nitric oxide (NO) release, TNF-α, IL-1β, in-
tracellular ROS and NF-κB activation from 
cultured rat brain microglial cells (Nam et 
al., 2010). Crocin showed antioxidant activi-
ty in the liver and kidney of streptozotocin-
induced diabetic rats (Rajaei et al., 2013). 
Thushara et al. (2013) showed that platelet 
aggregation induced by oxidative stress was 
inhibited by crocin through an anti-apoptotic 
pathway. In another study, cyclophospha-
mide-induced organ toxicity was prevented 
by crocin through modulating antioxidant 
status and inflammatory cytokines (Jnanesh-
wari et al., 2013). 
Other potential protective effects of the 
extract might be due to the antispasmodic 
properties of flavonoids contents present in 
the saffron’s extract, known to possess anti-
spasmodic and Ca2+ channel blocking activi-
ties (Revuelta et al., 1997). 
Given that infection is probably to be as-
sociated with urolithiasis process, antimicro-
bial activity may also contribute to antilithi-
atic effect of saffron (Vahidi et al., 2010). 
Taken together it is suggested that aque-
ous extract of Crocus sativus could be useful 
as either alternative or an adjunctive therapy 
in the management of kidney stones. Howev-
er, the exact mechanisms underlying this effect 
are still unknown, but are apparently related to 
antioxidant property and lowering of some uri-
nary concentrations of stone forming constitu-
ents.  
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